Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIonis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
39.42 USD 0.62 ( 1.60%)
Last update at 2026-11-06T21:04:00Z
VOLUME
2883290
Market Cap
7852.21M

Momentum Score

…

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
38.53
Low
40.00
High
52 Week Price Range
46.72
Low
86.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ionis Pharmaceuticals develops RNA-targeted antisense oligonucleotide therapies for genetic, neurological and cardiometabolic diseases. Growth may be driven by a diversified pipeline, licensing and collaboration revenues with larger drugmakers, and incremental improvements in its antisense platform. Investors may find it attractive for technology leadership in RNA therapeutics and potential recurring partner income as programs advance.

Key risks include clinical or regulatory setbacks, reliance on partner royalties and milestone payments, high R&D spending and patent or competitive challenges that could limit commercialization.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
38.80
Dividend Yield
-
Revenue TTM
874.09M
Revenue Per Share
5.36
Gross Profit TTM
-60.60M
Debt / Equity
5.35
ROE
-105.50%
Net Debt
2242.07M
ROCE
-11.20%
Diluted EPS TTM
-3.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -380.00M -460.07M -333.96M -258.00M -30.00M
Minority interest - - - 0.00M 0.00M
Net income -381.00M -453.90M -366.29M -270.00M -29.00M
Selling general administrative 393.90M 267.50M 232.60M 150.30M 170.90M
Selling and marketing expenses - 0.03M - 0.70M 15.10M
Gross profit 928.00M 693.92M 778.51M 573.00M 799.00M
Reconciled depreciation 22.69M 21.99M 22.50M 22.11M 19.56M
Ebit -307.00M -375.71M -258.37M -411.00M -30.00M
Ebitda -286.75M -353.72M -235.87M -561.00M -21.00M
Depreciation and amortization 20.25M 21.99M 22.50M -150.00M 9.00M
Non operating income net other - - - 160.33M 10.39M
Operating income -382.00M -475.08M -353.73M -411.00M -30.00M
Other operating expenses 1326.00M 1180.22M 1141.38M 998.00M 840.00M
Interest expense 90.54M 90.45M 81.46M 8.12M 4.30M
Tax provision 1.79M -6.17M 32.32M 11.74M -1.00M
Net interest income -90.08M -90.46M -81.50M -8.12M -9.20M
Income tax expense 1.00M -6.17M 32.32M 12.00M -1.00M
Total revenue 944.00M 705.14M 787.65M 587.00M 810.00M
Total operating expenses 1310.00M 1169.00M 1132.24M 984.00M 829.00M
Cost of revenue 16.00M 11.21M 9.13M 14.00M 11.00M
Total other income expense net 2.00M 15.01M 19.77M 153.00M -5.11M
Net income from continuing ops -381.39M -453.90M -366.29M -269.72M -28.60M
Net income applicable to common shares - - - -269.72M -28.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3523.84M 3003.68M 2990.07M 2534.00M 2612.00M
Intangible assets - - - - 29.00M
Other current assets 247.00M 217.93M 184.45M 190.00M 168.00M
Total liab 3034.75M 2415.32M 2603.39M 1961.00M 1840.00M
Total stockholder equity 489.09M 588.35M 386.69M 573.00M 772.00M
Other current liab 226.58M 178.05M 217.77M 195.54M 127.57M
Common stock 0.16M 0.16M 0.14M 0.14M 0.14M
Capital stock 0.16M 0.16M 0.14M 0.14M 0.14M
Retained earnings -2631.20M -2249.81M -1795.91M -1429.62M -1159.90M
Other liab - - - 287.77M 352.00M
Other assets - - - 34.97M 319.00M
Cash 372.26M 242.08M 399.27M 1987.00M 2115.00M
Total current liabilities 781.57M 309.32M 448.09M 312.00M 241.00M
Current deferred revenue 73.76M 78.99M 151.13M 91.00M 98.00M
Net debt 2242.07M 1174.49M 1054.27M -642.00M -954.00M
Short term debt 453.15M 9.28M 53.16M 7.54M 3.53M
Short long term debt 454.69M 9.28M 53.16M 7.54M 3.53M
Short long term debt total 2614.32M 1416.57M 1453.54M 1345.00M 1161.00M
Other stockholder equity 3145.40M 2868.81M 2182.45M 2059.96M 1964.43M
Property plant equipment - - - 74.29M 178.07M
Total current assets 2990.00M 2620.29M 2641.85M 2203.00M 2345.00M
Net tangible assets - - - 572.89M 742.73M
Short term investments 2305.18M 2055.58M 1931.93M 1710.40M 1245.78M
Net receivables 66.00M 92.19M 97.78M 26.00M 62.00M
Long term debt 1347.44M 1245.48M 1229.50M 1182.72M 1221.15M
Inventory 10.05M 12.51M 28.43M 22.03M 24.81M
Accounts payable 28.08M 42.96M 26.03M 17.92M 11.90M
Accumulated other comprehensive income -25.28M -30.81M -32.65M -57.48M -32.67M
Common stock total equity - - - 0.14M 0.14M
Retained earnings total equity - - - -1429.62M -1159.90M
Non currrent assets other 119.39M 86.25M 62.29M 75.00M 59.99M
Non current assets total 533.20M 383.38M 348.22M 331.00M 267.00M
Capital lease obligations 262.38M 161.81M 170.88M 178.94M -
Long term debt total - - - 1175.59M 1221.15M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -220.69M -134.03M 24.73M -262.64M 212.81M
Change to liabilities - - - 64.37M -42.59M
Total cashflows from investing activities -277.78M -134.03M - -262.64M 194.91M
Net borrowings 502.19M -44.67M - -50.69M 418.30M
Total cash from financing activities 675.84M 478.06M 644.08M -55.30M 245.93M
Change to operating activities - - - 32.38M -36.18M
Net income -381.39M -453.90M -366.29M -269.72M -28.60M
Change in cash 130.18M -157.19M 122.79M -592.72M 471.53M
Begin period cash flow 242.08M 399.27M 276.47M 869.19M 397.66M
End period cash flow 372.26M 242.08M 399.27M 276.47M 869.19M
Total cash from operating activities -268.58M -500.95M -307.51M -274.37M 30.80M
Issuance of capital stock 192.60M 522.73M 9.02M 6.37M 11.56M
Depreciation 22.69M 19.65M 22.50M 22.11M 19.56M
Other cashflows from investing activities -5.64M -5.06M - 249.71M -5.95M
Dividends paid - - - 10.95M 16.73M
Change to inventory -13.67M -5.07M -6.39M 2.77M -2.84M
Change to account receivables 26.13M 5.59M -72.06M 36.36M 5.05M
Sale purchase of stock - - - -10.95M -16.73M
Other cashflows from financing activities 675.84M 522.73M 1082.74M -0.03M 570.02M
Change to netincome - - - 103.05M 130.92M
Capital expenditures 51.44M 45.28M 28.01M 20.10M 17.90M
Cash flows other operating - - - -204.34M -66.67M
Exchange rate changes - - - - -0.11M
Cash and cash equivalents changes - - - -592.30M 471.53M
Change in working capital -51.22M -209.39M -77.26M 7.57M -113.82M
Stock based compensation 133.87M 130.20M 105.81M 100.26M 120.68M
Other non cash items 7.45M 12.49M 29.94M -134.59M 7.67M
Free cash flow -320.03M -546.23M -335.52M -294.47M 12.90M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IONS
Ionis Pharmaceuticals Inc		 0.62
1.60%		 39.42 - 90.91 8.98 19.44 9.28 135.77
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

2855 Gazelle Court, Carlsbad, CA, United States, 92010

760 931 9200

https://www.ionis.com

1480

Name Title Year Born
Dr. Brett P. Monia Ph.D. Founder, CEO & Director 1961
Ms. Elizabeth L. Hougen Exec. VP of Fin. & CFO 1962
Ms. Onaiza Cadoret-Manier Exec. VP, Chief Global Product Strategy & Operations Officer 1965
Mr. Patrick R. O'Neil Esq. Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. 1974
Dr. Stanley T. Crooke Scientific Advisor 1945
Ms. B. Lynne Parshall Esq., J.D. Sr. Strategic Advisor & Director 1954
Dr. Eric E. Swayze Ph.D. Exec. VP of Research 1966
Mr. Joel Edwards VP of Corp. Operations 1961
Mr. Darren Gonzales Chief Accounting Officer & Sr. VP NA
Dr. C. Frank Bennett Exec. VP & Chief Scientific Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…